World

Rain and mud leave Burning Man revelers stranded in Nevada desert

Sep 03, 2023

California [US], September 3: Tens of thousands of revelers attending the Burning Man festival in the Nevada desert have been asked to shelter in place and conserve food and water on Saturday after a rainstorm turned the site into mud.
Access to and from Black Rock City, the event's site, was closed "for the remainder of the event," organizers said in a statement on social media.
"Rain over the last 24 hours has created a situation that required a full stop of vehicle movement on the playa. More rain is expected over the next few days and conditions are not expected to improve enough to allow vehicles to enter the playa," the U.S. Bureau of Land Management said, according to local media reports.
More than 60,000 participants travel to and from the remote area in northwest Nevada every year, according to the event's website, gathering in the temporary city to make art, dance, and enjoy community.
The festival gets its name from its culminating event, the burning of a large wooden structure called the Man on the penultimate night.
The gathering, which originated as a small function in 1986 on a San Francisco beach and is now also attended by celebrities and social media influencers, was scheduled to run from Aug. 27 until Sept. 4.
Source: Fijian Broadcasting Corporation

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025